Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Garraway

Showing results (361-370 of 549) with videos related to

Pageof 55
Sort By:
Genetics in Medicine : Official Journal of the American College of Medical Genetics|February 12, 2016
Oncologists' and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq studyStacy W Gray, Elyse R Park, Julie Najita, et al.
Cancer Research|September 24, 2016
High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer CellsThomas Horn, Stéphane Ferretti, Nicolas Ebel, et al.
Cancer Research|June 16, 2016
Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor OutcomeSungyong You, Beatrice S Knudsen, Nicholas Erho, et al.
Cancer Discovery|February 3, 2019
MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in <i>BRAF-, NRAS</i>-, and <i>NF1</i>-Mutant MelanomasOphélia Maertens, Ryan Kuzmickas, Haley E Manchester, et al.
Cell Reports|October 21, 2016
Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense MutantsLisa Brenan, Aleksandr Andreev, Ofir Cohen, et al.
Nature Medicine|February 25, 2014
ARID1B is a specific vulnerability in ARID1A-mutant cancersKatherine C Helming, Xiaofeng Wang, Boris G Wilson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2011
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitorsPatrick A Oberholzer, Damien Kee, Piotr Dziunycz, et al.
Blood|June 4, 2010
Recurrent BRAF mutations in Langerhans cell histiocytosisGayane Badalian-Very, Jo-Anne Vergilio, Barbara A Degar, et al.
JCO Oncology Practice|May 29, 2026
Development and External Validation of a Machine Learning-Based Risk Classification Score for Prostate Cancer-Specific Cardiovascular RiskNickolas Stabellini, Tarek Nahle, Viraj Shah, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 17, 2009
MEK1 mutations confer resistance to MEK and B-RAF inhibitionCaroline M Emery, Krishna G Vijayendran, Marie C Zipser, et al.
Pageof 55

Showing results (361-370 of 549) with videos related to

Sort By:
Pageof 55
Genetics in Medicine : Official Journal of the American College of Medical Genetics|February 12, 2016
Oncologists' and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq studyStacy W Gray, Elyse R Park, Julie Najita, et al.
Cancer Research|September 24, 2016
High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer CellsThomas Horn, Stéphane Ferretti, Nicolas Ebel, et al.
Cancer Research|June 16, 2016
Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor OutcomeSungyong You, Beatrice S Knudsen, Nicholas Erho, et al.
Cancer Discovery|February 3, 2019
MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in <i>BRAF-, NRAS</i>-, and <i>NF1</i>-Mutant MelanomasOphélia Maertens, Ryan Kuzmickas, Haley E Manchester, et al.
Cell Reports|October 21, 2016
Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense MutantsLisa Brenan, Aleksandr Andreev, Ofir Cohen, et al.
Nature Medicine|February 25, 2014
ARID1B is a specific vulnerability in ARID1A-mutant cancersKatherine C Helming, Xiaofeng Wang, Boris G Wilson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2011
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitorsPatrick A Oberholzer, Damien Kee, Piotr Dziunycz, et al.
Blood|June 4, 2010
Recurrent BRAF mutations in Langerhans cell histiocytosisGayane Badalian-Very, Jo-Anne Vergilio, Barbara A Degar, et al.
JCO Oncology Practice|May 29, 2026
Development and External Validation of a Machine Learning-Based Risk Classification Score for Prostate Cancer-Specific Cardiovascular RiskNickolas Stabellini, Tarek Nahle, Viraj Shah, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 17, 2009
MEK1 mutations confer resistance to MEK and B-RAF inhibitionCaroline M Emery, Krishna G Vijayendran, Marie C Zipser, et al.
Pageof 55